FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a method for the production of T-cell with a chimeric antigen receptor, having a decreased level of polypeptides of a granulocyte-macrophage colony-stimulating factor (GM-CSF). A method for improvement of T-cell effector functions of T-cell with a chimeric antigen receptor is also disclosed.
EFFECT: invention is effective for the treatment of a mammal suffering from cancer.
17 cl, 21 dwg, 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2798348C2 |
CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
COMPOSITIONS AND METHODS FOR INHIBITING T-CELL DEPUTY | 2018 |
|
RU2804282C2 |
THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
Authors
Dates
2023-01-12—Published
2019-05-31—Filed